Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Diouf, Momar ^a,b   Chibaudel, Benoist ^c   Filleron, Thomas ^e   Tournigand, Christophe ^f   Hug de Larauze, Marine ^d   Garcia Larnicol, Marie Line ^c   Dumont, Sarah ^c   Louvet, Christophe ^g   Perez Staub, Nathalie ^c   Hadengue, Alexandra ^d   de Gramont, Aimery ^c   Bonnetain, Franck ^b,d  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d GERCOR (Franch Oncology Research Group)   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; LACTATE DEHYDROGENASE; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; COMPARATIVE STUDY; FEMALE; HUMAN; KOHNE PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; SURVIVAL PREDICTION;

ACTIVITIES OF DAILY LIVING; AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL ANALYSIS;

EID: 84901279852     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-12-69     Document Type: Article

References (25)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Field K, Lipton L. Metastatic colorectal cancer-past, progress and future. World J Gastroenterol 2007, 13(28):3806-3815.
3. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005, 16:1311-1319. 10.1093/annonc/mdi246, 15870084.
4. Jessup JM, Gunderson LL, Greene FL, Washington MK, Compton CC, Sobin LH, Minsky B, Goldbert RM, Hamilton SR. Staging System for Colon and Rectal Carcinoma. Ann Surg Oncol 2010, 2011(18):1513-1517.
5. Köhne CH, Cunningham D, Di Constanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002, 13(2):308-317. 10.1093/annonc/mdf034, 11886010.
6. Chibaudel B, Bonnetain F, Tournigand C, Bengrine-Lefevre L, Teixeira L, Artru P, Desramé J, Larsen AK, André T, Louvet C, de Gramont A. Simplified prognostic model in patients with oxaliplatin-based or irinoecan-based first-line chemotherapy for metastatic colorectal cancer: A GERCOR study. Oncologist 2011, 16(9):1228-1238. 10.1634/theoncologist.2011-0039, 3228179, 21859820.
7. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics. Multivariable prognostic models issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996, 15:361-387. 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4, 8668867.
8. Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009, 7:102. 10.1186/1477-7525-7-102, 2805623, 20030832.
9. Quinten C, Coens C, Mauer M, Comte S, Sprangers MA, Cleeland C, Osoba D, Bjordal K, Bottomley A, . EORTC Clinical Groups Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009, 10:865-871. 10.1016/S1470-2045(09)70200-1, 19695956, EORTC Clinical Groups.
10. Diouf M, Filleron T, Barbare JC, Fin L, Picard C, Bouché O, Dahan L, Paoletti X, Bonnetain F. The added value of quality of life (QoL) for prognoses of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol 2013, 58:509-521. 10.1016/j.jhep.2012.11.019, 23178978.
11. Braun DP, Gupta D, Grutsch JF, Staren ED. Can changes in health related quality of life scores predict survival in stage III and IV colorectal cancer?. Qual Life Res 2011, 9:62.
12. Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F, . Chronotherapy Group of the European Organisation for Research and Treatment of Cancer Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2008, 26:2020-2026. 10.1200/JCO.2007.12.3117, 18421055, Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
13. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006, 24:394-400. 10.1200/JCO.2005.03.0106, 16421419.
14. Group EQ. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
15. Schemper M. Predictive accuracy and explained variation. Stat Med 2003, 22:2299-2308. 10.1002/sim.1486, 12854094.
16. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21. 10.1002/sim.4085, 3341973, 21204120.
17. CLARK TG, Altman DG. Developing a prognostic model in presence of missing data: an ovarian cancer study. J Clin Epidemiol 2003, 56:28-37. 10.1016/S0895-4356(02)00539-5, 12589867.
18. Marshall M, Altman DG, Royston P, Holder RL. Comparaison of techniques for handling missing covariate data within prognostic modelling studies: a simulation study. BMC Med Res Methodol 2010, 10:7. 10.1186/1471-2288-10-7, 2824146, 20085642.
19. Van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999, 18:681-694. 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R, 10204197.
20. Marshall M, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009, 9:57. 10.1186/1471-2288-9-57, 2727536, 19638200.
21. Tournoux-Facon C, Paoletti X, Barbare JC, Bouché O, Rougier P, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Bedenne L, Bonnetain F. Development and validation of a new prognostic score of death for patients with hepatocellular carcinoma in palliative setting. J Hepatol 2011, 54(1):108-114. 10.1016/j.jhep.2010.06.015, 21047696.
22. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
23. Mauer M, Bottomley A, Coens C, Gotay C. Prognostic factor analysis of health-related quality of life data in cancer: statistical methodological evaluation. Expert Rev Pharmacoecon Outcomes Res 2008, 8(2):179-196. 10.1586/14737167.8.2.179, 20528407.
24. Vach W, Blettner M. Missing data in epidemiologic studies. Encyclopedia of Biostatistics 1998, 2641-2654. New York: John Wiley & Sons.
25. Moons KGM, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and prognostic research: what, why, and how?. Br Med J 2009, 338:b375. 1317-1320.